Immunotherapy for pleural mesothelioma: from innovation to the frontlines of core clinical questions
{{output}}
In August 2018, Japan's Pharmaceuticals and Medical Devices Agency (PMDA) became the first in the world to approve immune checkpoint inhibitor (ICI) monotherapy with nivolumab for previously treated, unresectable, advanced, or recurrent pleural mesothelioma (... ...
